Volume 3.15 | Apr 27

Prostate Cell News 3.15 April 27, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY

A Transcriptional Repressor Co-Regulatory Network Governing Androgen Response in Prostate Cancers
Using ChIP-Seq, researchers generated extensive global binding maps of the androgen receptor, ERG, and commonly over-expressed transcriptional corepressors including HDAC1, HDAC2, HDAC3, and EZH2 in prostate cancer cells. [EMBO J] Abstract

Apply Now: Mammary Stem Cell Training Course (June 2-3 2012) in Vancouver, Canada.
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Multivalent Peptidomimetic Conjugates: A Versatile Platform for Modulating Androgen Receptor Activity
Scientists identified a linear and a cyclic conjugate that exhibits potent anti-proliferative activity in LNCaP-abl cells, a model of therapy-resistant prostate cancer.[J Am Chem Soc]
Abstract

ESE3/EHF Controls Epithelial Cell Differentiation and Its Loss Leads to Prostate Tumors with Mesenchymal and Stem-Like Features
Researchers showed that the endogenously expressed ETS transcription factor ESE3/EHF controls prostate epithelial cell differentiation and stem-like potential. [Cancer Res] Abstract

Androgen-Regulated Processing of the Oncomir MiR-27a, which Targets Prohibitin in Prostate Cancer
Scientists demonstrated that microRNA-27a (miR-27a) is an androgen-regulated oncomir in prostate cancer, acting via targeting the tumor suppressor and androgen receptor corepressor, Prohibitin. [Hum Mol Genet] Abstract

Aloe-Emodin Suppresses Prostate Cancer by Targeting the mTOR Complex 2
Investigators found that mammalian target of rapamycin complex 2 (mTORC2) plays an important role in prostate cancer development and aloe-emodin suppresses prostate cancer progression by targeting mTORC2. [Carcinogenesis] Abstract

Prostate Cancer Cells and Bone Stromal Cells Mutually Interact with Each Other through Bone Morphogenetic Protein-Mediated Signals
Researchers investigated the roles of bone morphogenetic proteins in the interactions between prostate cancer cells and bone stromal cells. [J Biol Chem] Abstract

Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells
Scientists demonstrated that phosphatase and tensin homolog (PTEN) expression inversely correlates with sunitinib resistance in renal and prostate cancer cells. Restoration of PTEN expression markedly increases sensitivity of tumor cells to sunitinib both in vitro and in vivo. [Mol Cancer Ther] Abstract

Inducible Silencing of Protein Kinase D3 Inhibits Secretion of Tumor-Promoting Factors in Prostate Cancer
Using both a stable inducible knockdown cell model and a transient knockdown system employing multiple siRNAs, researchers demonstrated that silencing of endogenous protein kinase D3 significantly reduces prostate cancer cell proliferation, migration, and invasion. [Mol Cancer Ther] Abstract

Modulation of the Activity of Sp Transcription Factors by Mithramycin Analogues as a New Strategy for Treatment of Metastatic Prostate Cancer
Researchers studied two mithramycin A (MTM-A) analogues, which had been generated by genetically engineering of the MTM-A biosynthetic pathway, and evaluated their activity in human prostate cancer in cell cultures and mouse models. [PLoS One] Abstract

Curcumin Attenuates ß-Catenin Signaling in Prostate Cancer Cells through Activation of Protein Kinase D1
Researchers demonstrated that curcumin activates protein kinase D1, resulting in changes in ß-catenin signaling by inhibiting nuclear ß-catenin transcription activity and enhancing the levels of membrane ß-catenin in prostate cancer cells. [PLoS One] Abstract


CLINICAL RESEARCH

A Switch from GnRH Agonist to GnRH Antagonist in Castration-Resistant Prostate Cancer Patients Leads to a Low Response Rate on PSA
Investigators evaluated the impact of a switch from GnRH agonist to antagonist in patients with castration-resistant prostate cancer on PSA and testosterone levels at three months. [World J Urol] Abstract

Long-Term Dynamics of Bone Mineral Density during Intermittent Androgen Deprivation for Men with Nonmetastatic, Hormone-Sensitive Prostate Cancer
Researchers investigated changes in bone mineral density and fracture risk in men who received intermittent androgen deprivation for nonmetastatic, hormone-sensitive prostate cancer. [J Clin Oncol] Abstract

[New Webinar] Discover How to Reduce Variability in Primary Neuron Cultures with NeuroCult SM

INDUSTRY NEWS

New Veridex Alliance Drives Study of Circulating Tumor Cells in Men with Metastatic Prostate Cancer
Veridex, LLC announced it has joined with Novartis Pharmaceuticals Corporation in an educational alliance to encourage and facilitate research involving circulating tumor cells as a potential biomarker in metastatic prostate cancer. [PR Newswire] Press Release


Ezose Sciences and Hirosaki University to Collaborate in Glycomics Research to Find New Cancer Biomarkers

Ezose Sciences Inc. and Hirosaki University announced that they have formed a collaboration in glycomics research to identify new biomarkers for use in predicting and monitoring the progression of prostate cancer and other urological cancers. [BusinessWire] Press Release


OICR Announced New Funding for Imaging Research in Ontario to Bring Personalized Medicine to Patients

Ontario Institute for Cancer Research (OICR) announced new funds to further enhance imaging research in Ontario and to develop improved imaging tools for more personalized diagnosis and treatment of cancer patients worldwide. [Ontario Institute for Cancer Research] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS

NEW Exploratory Clinical Development World Europe
May 22-24, 2012
London, United Kingdom

Visit our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)


Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)


Postdoctoral Fellow – Prostate Cancer (University of Colorado)

Postdoctoral Fellow/Associate Research Scientist – Prostate Cancer (Columbia University Medical Center)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

E-mail info@connexoncreative.com to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us